Poxel’s Pioglitazone Formulation Meets Key Endpoints In Phase II NASH Study

 
• By Joseph Haas

A version of the diabetes drug intended to reduce PPAR gamma activation shows hoped for benefits and safety in a Phase II study. Poxel will now choose to advance one of two mid-stage NASH candidates.

Tough choice
Poxel now must make a decision on which Phase II NASH drug to take forward • Source: Shutterstock

More from Clinical Trials

More from R&D